About pcm

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

Editorial Commentary 
BRAF V600E mutant, PD-L1 TPS 90% NSCLC: 1st line treatment with targeted therapy
Edwin H. Yau
Precision Cancer Medicine  
2021;
4:
10  
Editorial Commentary 
The role of Anti-PD-1/PD-L1 monotherapy as first-line treatment of metastatic NSCLC without targetable mutations and PD-L1 TPS 1–49%
Arpeet T. Shah, Joel W. Neal
Precision Cancer Medicine  
2021;
4:
9  
Editorial Commentary 
Management of acquired resistance to ALK inhibitors: repeat biopsy to characterize mechanisms of resistance does not significantly impact clinical outcomes
Naiyarat Prasongsook, Thanyanan Reungwetwattana
Precision Cancer Medicine  
2021;
4:
8  
Editorial Commentary 
Concerns and controversies regarding ipilimumab-based immunotherapy in the first-line treatment of non-small cell lung cancer
Ivy Riano, Narjust Duma
Precision Cancer Medicine  
2021;
4:
7  
Editorial Commentary 
ADAURA: The role of adjuvant EGFR TKI and future consideration (Pro)
Patrick C. Ma
Precision Cancer Medicine  
2021;
4:
6  
Case Report 
Precision oncology in EGFR positive non-small cell lung cancer: breaking the 10-year barrier—a case report
Camila Ordóñez-Reyes, Alejandro Ruiz-Patiño, Oscar Arrieta, Lucia Zatarain-Barrón, Leonardo Rojas, Gonzalo Recondo, Luisa Ricaurte, Andrés F. Cardona, on behalf of Latin American Consortium for the Investigation of Lung Cancer (CLICaP)
Precision Cancer Medicine  
2021;
4:
5  
Case Report 
Unusual pattern of recurrence and atypical visceral metastases in extremity soft tissue sarcoma: a case report
Paula Sedano, Carmen González-San Segundo, Marta Rodríguez-Pertierra, Francisco Díaz-Gutiérrez, Adriana Medrano, Carolina Agra-Pujol
Precision Cancer Medicine  
2021;
4:
4  
Review Article 
A narrative review of immune checkpoint inhibitors in early stage triple negative breast cancer
Ana-Alicia Beltran-Bless, Terry L. Ng
Precision Cancer Medicine  
2021;
4:
3  
Editorial Commentary 
Checkpoint inhibitors first in patients with metastatic non-small cell lung cancer harboring BRAFV600E mutation with PD-L1 90%—a debate in a niche population
Yusra F. Shao, Ammar Sukari, Misako Nagasaka
Precision Cancer Medicine  
2020;
3:
35  
Editorial Commentary 
CM227/CM9-LA: evidence supporting ipilimumab-based immunotherapy in the first-line treatment of metastatic NSCLC
Emily F. Collier, Sarah B. Goldberg
Precision Cancer Medicine  
2020;
3:
34  
Editorial Commentary 
ADAURA: a definitive answer to the wrong question
Howard West
Precision Cancer Medicine  
2020;
3:
32  
Letter to the Editor 
Utility of high-throughput sequencing of T-cell receptor rearrangements in assessing treatment response in patients with mature T-cell lymphoma
Pooja M. Phull, Carlyn R. Tan, Henry C. Fung, Paul A. Fields, Yang Liu, Jasmine Zain, Nathan H. Fowler, R. Katherine Alpaugh, Yasuhiro Oki, Stefan K. Barta
Precision Cancer Medicine  
2020;
3:
31  
Case Report 
Use of 3D-planning and tantalum in revision total hip arthroplasty after failed iliac bone allograft for Ewing sarcoma: a case report
Michele Fiore, Andrea Sambri, Riccardo Zucchini, Claudio Giannini, Fulvia Taddei, Massimiliano De Paolis
Precision Cancer Medicine  
2020;
3:
30  
Case Report 
Effective tyrosine kinase inhibitor re-treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer patient: a case report
Alessandro Galletti, Marco Russano, Fabrizio Citarella, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini
Precision Cancer Medicine  
2020;
3:
29  
Case Report 
Feasibility of ultra-central stereotactic ablative irradiation in lung cancer undergoing nivolumab: a case report
Valerio Nardone, Maria Grazia Calvanese, Maria Mormile, Francesca Maria Giugliano, Pierpaolo Correale, Alfonso Reginelli, Salvatore Cappabianca, Cesare Guida
Precision Cancer Medicine  
2020;
3:
28  
Case Report 
Micrometastatic breast cancer presenting as abnormal uterine bleeding: case report
Noah Gomez, Mark McNeely, Jaya Ruth Asirvatham, Ashwin S. Akki
Precision Cancer Medicine  
2020;
3:
27  
Review Article 
A narrative review of BRAF alterations in human tumors: diagnostic and predictive implications
Lynette M. Sholl
Precision Cancer Medicine  
2020;
3:
26  

Editorial

AR-V7 and treatment selection in advanced prostate cancer: are we there yet?
Diogo A. Bastos, Emmanuel S. Antonarakis

Case Report: Precision Oncology Tumor Board

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Kartik Sehgal, Andrew J. Piper-Vallillo, Hollis Viray, Adeel M. Khan, Deepa Rangachari, Daniel B. Costa